Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MS-209 Schering.

Jacques Robert1

  • 1Institut Bergonié and Université Victor Segalen, 229 Cours de l'Argonne, 33076 Bordeaux Cedex, France. robert@bergonie.org

Current Opinion in Investigational Drugs (London, England : 2000)
|January 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glutathione impacts both <i>Batrachochytrium dendrobatidis</i> virulence and amphibian cellular defence in a chytridiomycosis model.

bioRxiv : the preprint server for biology·2026
Same author

Glutathione Impacts Both Batrachochytrium dendrobatidis Virulence and Amphibian Cellular Defense in a Chytridiomycosis Model.

MicrobiologyOpen·2026
Same author

Using fluorescent in vitro amphibian cell infection models to quantify pathogenicity of Batrachochytrium dendrobatidis.

Methods (San Diego, Calif.)·2026
Same author

A miRNA screen reveals a transcriptional network controlling the initiation of mammary organoids.

The FEBS journal·2026
Same author

Evolutionary Perspective of Nonclassical MHC Class I and Innate-like T Cells Relevance in Immune Surveillance.

Cells·2025
Same author

[The authors' response to the letter to the editor "In the (scientific) search for known risk factors"].

Bulletin du cancer·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

MS-209, a novel sphingomyelin synthase inhibitor, is being developed to treat multidrug-resistant tumors. Early trials are underway for breast and lung cancers, targeting key drug resistance mechanisms.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer therapy.
  • P-glycoprotein and multidrug resistance-associated protein-1 are key efflux pumps involved in MDR.
  • Targeting MDR mechanisms is crucial for improving cancer treatment outcomes.

Purpose of the Study:

  • To evaluate MS-209, a quinolone-derived sphingomyelin synthase inhibitor, as a potential treatment for multidrug-resistant tumors.
  • To investigate the efficacy of MS-209 in blocking P-glycoprotein and multidrug resistance-associated protein-1.
  • To advance MS-209 through clinical trials for specific cancer types.

Main Methods:

  • MS-209, a sphingomyelin synthase inhibitor, was developed.
  • Phase II clinical trials were initiated to assess MS-209.

Related Experiment Videos

  • Trials focused on patients with breast cancer and non-small-cell lung cancer.

    • Main Results:

    • MS-209 demonstrated potential as a sphingomyelin synthase inhibitor.
    • The drug targets P-glycoprotein and multidrug resistance-associated protein-1.
    • Phase II trials in breast and non-small-cell lung cancer were initiated by March 2003.

    Conclusions:

    • MS-209 shows promise in overcoming multidrug resistance in cancer.
    • Further clinical evaluation is warranted to establish its therapeutic role.
    • Targeting sphingomyelin synthase may offer a novel strategy against resistant tumors.